---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-286158"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:48:02.724102+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cogent completes $230M 1.625% convertible senior notes offering due 2031

## Summary
- Aggregate principal $230M including full exercise of $30M over-allotment option by underwriters.
- Notes bear 1.625% interest payable semiannually on May 15 and Nov 15, starting May 15, 2026; mature Nov 15, 2031.
- Initial conversion rate 22.2469 shares per $1,000 principal (conversion price ~$44.95); settlement in cash, stock, or combo at company's election.
- Notes are senior unsecured obligations; redeemable at company's option after Nov 20, 2029 subject to stock price conditions.
- Noteholders may require repurchase upon a Fundamental Change (e.g., business combination, delisting) at principal plus accrued interest.

## SEC filing metadata
- accession: 0001193125-25-286158
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312525286158/0001193125-25-286158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312525286158/d888858d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-286158
- JSON: https://secwatch.observer/filing/0001193125-25-286158.json
- Plain text: https://secwatch.observer/filing/0001193125-25-286158.txt

## Key facts
- Debt Financings
  Cogent Biosciences, Inc. incurred convertible notes of $230,000,000 aggregate principal amount with U.S. Bank Trust Company, National Association at 1.625% per year maturing November 15, 2031.
  - Instrument: convertible notes
  - Principal: $230,000,000 aggregate principal amount
  - Counterparty: U.S. Bank Trust Company, National Association
  - Rate: 1.625% per year
  - Maturity: November 15, 2031
  - Event: incurrence
  source text: On November 18, 2025, Cogent Biosciences, Inc. (the “Company”) completed its previously-announced public offering (the “Offering”) of $230,000,000 aggregate principal amount of its 1.625% Convertible Senior Notes due 2031
  evidence_url: https://www.sec.gov/Archives/edgar/data/1622229/000119312525286158/0001193125-25-286158-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.